Across TCGA pan-cancer cohorts, ZNF260 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ZNF260 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ZNF260 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF260 expression acts as an unfavorable survival marker.
LUSC are the cancer types where ZNF260 Mutation most reproducibly stratifies survival.